Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Seong Hyun | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Cho, Seok Goo | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Hong, Jun Shik | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.date.accessioned | 2021-09-04T17:39:02Z | - |
dc.date.available | 2021-09-04T17:39:02Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93945 | - |
dc.description.abstract | The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen has been widely used for lymphoblastic lymphoma (LBL) as a primary treatment. However, there is few data about its treatment outcome in Asian patients. Thus, we conducted this study to evaluate the efficacy of hyper-CVAD induction and stem cell transplantation (SCT) consolidation in LBL patients. The treatment responses of 49 patients treated with the hyper-CVAD regimen were retrospectively analyzed in 13 institutions. Given 24 patients who responded to hyper-CVAD underwent consolidation treatment with SCT, overall survival (OS) and progression-free survival (PFS) of patients who received SCT were compared with patients who did not. The overall response rate was 79 %: 73 % (36/49) complete responses, 6 % (3/49) partial responses, and 4 % (2/49) induction deaths. The major limitation for the delivery of the planned hyper-CVAD cycles was hematological toxicity. Among 39 responders, 24 patients underwent autologous (n = 16) and allogeneic SCT (n = 8) consolidation. Their 3-year OS and PFS rates were 76 and 78 %, respectively, and there was no difference in survival outcomes between autologous and allogeneic SCT. However, 15 patients without SCT consolidation showed poorer PFS even though they all achieved complete response. Thus, only seven patients maintained their response at the time of analysis. In conclusion, the hyper-CVAD regimen is effective for remission induction in LBL, and SCT consolidation after hyper-CVAD induction produced better clinical outcomes than did continuation of hyper-CVAD. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | MARROW-TRANSPLANTATION | - |
dc.subject | CLINICAL-FEATURES | - |
dc.subject | LEUKEMIA | - |
dc.subject | TRIAL | - |
dc.subject | THERAPY | - |
dc.title | Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1007/s00277-014-2258-y | - |
dc.identifier.scopusid | 2-s2.0-84925543014 | - |
dc.identifier.wosid | 000350869900010 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.94, no.4, pp.617 - 625 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 94 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 617 | - |
dc.citation.endPage | 625 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | MARROW-TRANSPLANTATION | - |
dc.subject.keywordPlus | CLINICAL-FEATURES | - |
dc.subject.keywordPlus | LEUKEMIA | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Lymphoblastic lymphoma | - |
dc.subject.keywordAuthor | Hyper-CVAD | - |
dc.subject.keywordAuthor | Stem cell transplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.